Ramipril and Dermatomyositis - a phase IV clinical study of FDA data

Summary:

Dermatomyositis is reported as a side effect among people who take Ramipril (ramipril), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Gliclazide, and have Type 2 diabetes.

The phase IV clinical study analyzes which people have Dermatomyositis when taking Ramipril. It is created by eHealthMe based on reports of 144,209 people who have side effects when taking Ramipril from the FDA, and is updated regularly.

What is Ramipril?

Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,397 Ramipril users. Check the latest studies of Ramipril.

What is Dermatomyositis?

Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer) is found to be associated with 263 drugs and 415 conditions by eHealthMe. Check the latest studies of Dermatomyositis.

On Jul, 21, 2026

144,209 people reported to have side effects when taking Ramipril.
Among them, 40 people (0.03%) have Dermatomyositis.

Among these 40 people:

How long have people been on Ramipril when they have Dermatomyositis? *

What is the gender of people who have Dermatomyositis when taking Ramipril? *

female: 41.67 %
male: 58.33 %

What is the age of people who have Dermatomyositis when taking Ramipril? *

What are other drugs people take besides Ramipril? *

What are other side effects people have besides Dermatomyositis? *

Interstitial Lung Disease: 12 people, 30.00%
Rashes (redness): 4 people, 10.00%
Joint Pain: 4 people, 10.00%
Antisynthetase Syndrome (chronic autoimmune disease of unknown cause): 3 people, 7.50%
Body Temperature Increased: 3 people, 7.50%
Exercise Tolerance Decreased: 3 people, 7.50%
Dyspnea At Rest: 3 people, 7.50%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 5.00%
Polymyositis (inflammatory muscle disease that causes weakness of the skeletal muscles): 2 people, 5.00%
Weakness: 2 people, 5.00%

What are the existing conditions these people have? *

Type 2 Diabetes: 8 people, 20.00%
Dyslipidaemia (abnormal amount of lipids): 7 people, 17.50%
Glaucoma (increased fluid pressure in the eye with vision loss): 7 people, 17.50%
Gouty Arthritis (joint inflammation with crystal formation): 4 people, 10.00%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 2 people, 5.00%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 2.50%
Breast Cancer: 1 person, 2.50%
Diarrhea: 1 person, 2.50%
Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 2.50%
Thyroid Diseases: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Ramipril and have Dermatomyositis?

- Check whether Dermatomyositis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ramipril:

Ramipril (147,397 reports)

Dermatomyositis treatments and more:

Dermatomyositis (8,399 reports)

Browse all side effects of Ramipril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatomyositis:

Dermatomyositis (263 drugs)

Browse all the conditions that are associated with Dermatomyositis:

Dermatomyositis (415 conditions)

Related publications that referenced our studies

Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ramipril (the active ingredients of Ramipril) and Ramipril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.